ClinicalTrials.gg
CompletedNCT04756960Updated Mar 18, 2024Results posted

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

A Phase 1 interventional study of CHF6001 in Chronic Obstructive Pulmonary Disease (COPD) and COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 12
8 · median 46
Started
2021
with 3 others
Phase 1
7 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
12 of 12
Chiesi Farmaceutici S.p.A.

Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 1, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tanimilast

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 30 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.

Read the detailed description

This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.

The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14\^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.

Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • COPD

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Healthy subjects
  • Phase I
  • CHF6001
  • Tanimilast
  • Chiesi Farmaceutici S.p.A
04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedure;
  2. Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
  3. Male subjects aged 30 to 55 years inclusive;
  4. (BMI) within the range of 18 to 35 kg/m\^2 inclusive;
  5. Non- or ex-smoker who smoked \< 5 pack years and who stopped smoking > 1 year prior to screening;
  6. Good physical and mental status;
  7. Vital signs at screening within limits;
  8. 12-lead digitised (12-lead ECG) in triplicate considered as normal;
  9. Lung function measurements within normal limits at screening;
  10. Regular bowel movements at screening;
  11. Males with non-pregnant Women of (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical trial with an drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
  2. and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
  3. Clinically relevant abnormal laboratory values;
  4. Subjects with history of breathing problems;
  5. Positive to 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
  6. Positive results from the Hepatitis serology which indicates acute or chronic or at screening;
  7. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
  8. Positive urine test for cotinine;
  9. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
  10. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
  11. Intake of non-permitted concomitant medications in the predefined period;
  12. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
  13. Known intolerance and/or to any of the contained in the formulation used in the trial;
  14. Unsuitable veins for repeated venipuncture;
  15. Heavy caffeine drinker;
  16. Abnormal level at screening;
  17. Subjects using e-cigarettes within 6 months prior to screening;
  18. Subjects been involved in a study involving a 14\^C-labeled drug within the 12 months prior to enrollment;
  19. Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
  20. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    CHF6001

    single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of \[14\^C\]-labelled CHF6001

    Drug: CHF6001

Interventions

  • 4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001

06

What researchers measure

Primary outcomes

  1. PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total

    AUC(0-t_iv) for \[14\^C\] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  2. PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total

    C(max_iv) for \[14\^C\] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  3. PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total

    t(max_iv) for \[14\^C\] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  4. PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total

    Area under curve extrapolated to infinity (AUC(0-∞_iv) for \[14\^C\] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  5. PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total

    Terminal half-life t(1/2_iv) for \[14\^C\] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  6. PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total

    Blood to plasma ratio for \[14\^C\] total.

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

  7. PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001

    AUC(0-t_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  8. PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001

    C(max_iv) for \[14\^C\] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  9. PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001

    t(max_iv) for \[14\^C\] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  10. PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001

    Area under curve extrapolated to infinity (AUC0-∞_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  11. PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001

    Terminal half-life t(1/2_iv) for \[14\^C\] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  12. PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001

    Volume of distribution during the terminal phase (Vz_iv) of \[14\^C\] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  13. PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001

    Vdss_iv=Volume of distribution is calculated at steady-state for \[14\^C\] CHF6001 in plasma, after intravenous (iv) infusion administration.

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  14. PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001

    Systemic plasma clearance for \[14\^C\] CHF6001.

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

  15. PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001

    Blood to plasma ratio for \[14\^C\] CHF6001.

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

  16. PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001

    AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

  17. PK Parameter -- C(max_inh) -- Plasma -- CHF6001

    C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

  18. PK Parameter -- t(max_inh) -- Plasma -- CHF6001

    t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

  19. PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001

    AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

  20. PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001

    t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

  21. PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001

    Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

  22. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total

    Urine excreted fraction for cumulative \[14\^C\] total.

    Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.

  23. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001

    Urine excreted fraction for cumulative \[14\^C\]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.

    Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.

  24. PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total

    Fecal excreted fraction for cumulative \[14\^C\] total.

    Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

  25. PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001

    Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

    Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

  26. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total

    Urine and fecal excreted fraction for cumulative \[14\^C\] total.

    Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

  27. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001

    Urine and Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

    Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

07

Results

Posted Mar 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneCHF6001
Started8
Completed8
Not completed0

Outcome measures

PrimaryPK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total

AUC(0-t_iv) for \[14\^C\] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · h*ngEq/mL
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total
h*ngEq/mLCHF6001
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total5.4025 ± 16.7
PrimaryPK Parameter -- C(max_iv) -- Plasma -- [14^C] Total

C(max_iv) for \[14\^C\] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · ngEq/mL
PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total
ngEq/mLCHF6001
PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total0.7072 ± 21.6
PrimaryPK Parameter -- t(max_iv) -- Plasma -- [14^C] Total

t(max_iv) for \[14\^C\] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Median · h
PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total
hCHF6001
PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total0.217 (0.17 to 0.25)
PrimaryPK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total

Area under curve extrapolated to infinity (AUC(0-∞_iv) for \[14\^C\] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · h*ngEq/mL
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total
h*ngEq/mLCHF6001
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total6.0825 ± 19.6
PrimaryPK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total

Terminal half-life t(1/2_iv) for \[14\^C\] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Median · h
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total
hCHF6001
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total72.4057 (56.446 to 105.776)
PrimaryPK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total

Blood to plasma ratio for \[14\^C\] total.

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
Reported as:
Geometric mean · Ratio
PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total
RatioCHF6001
PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total0.6490 ± 23.9
PrimaryPK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001

AUC(0-t_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · h*ng/mL
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001
h*ng/mLCHF6001
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF60010.7825 ± 18.2
PrimaryPK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001

C(max_iv) for \[14\^C\] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · ng/mL
PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001
ng/mLCHF6001
PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF60010.6312 ± 19.1
PrimaryPK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001

t(max_iv) for \[14\^C\] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Median · h
PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001
hCHF6001
PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF60010.217 (0.17 to 0.25)
PrimaryPK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001

Area under curve extrapolated to infinity (AUC0-∞_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · h*ng/mL
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001
h*ng/mLCHF6001
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF60010.8138 ± 18.6
PrimaryPK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001

Terminal half-life t(1/2_iv) for \[14\^C\] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Median · h
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001
hCHF6001
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF600113.5816 (6.452 to 33.092)
PrimaryPK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001

Volume of distribution during the terminal phase (Vz_iv) of \[14\^C\] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · Litres
PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001
LitresCHF6001
PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001436.1078 ± 38.6
PrimaryPK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001

Vdss_iv=Volume of distribution is calculated at steady-state for \[14\^C\] CHF6001 in plasma, after intravenous (iv) infusion administration.

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · Litres
PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001
LitresCHF6001
PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001201.2514 ± 36.2
PrimaryPK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001

Systemic plasma clearance for \[14\^C\] CHF6001.

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Reported as:
Geometric mean · Litres/h
PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001
Litres/hCHF6001
PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF600121.9951 ± 18.6
PrimaryPK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001

Blood to plasma ratio for \[14\^C\] CHF6001.

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
Reported as:
Geometric mean · Ratio
PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001
RatioCHF6001
PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF60010.5166 ± 54.9
PrimaryPK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001

AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001

Time frame:
At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
Reported as:
Mean · h*pg/mL
PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001
h*pg/mLCHF6001
PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF600171088 ± 28.2
PrimaryPK Parameter -- C(max_inh) -- Plasma -- CHF6001

C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
Reported as:
Geometric mean · pg/mL
PK Parameter -- C(max_inh) -- Plasma -- CHF6001
pg/mLCHF6001
PK Parameter -- C(max_inh) -- Plasma -- CHF60011979 ± 22.5
PrimaryPK Parameter -- t(max_inh) -- Plasma -- CHF6001

t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
Reported as:
Median · h
PK Parameter -- t(max_inh) -- Plasma -- CHF6001
hCHF6001
PK Parameter -- t(max_inh) -- Plasma -- CHF60012.008 (2.00 to 3.75)
PrimaryPK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001

AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001

Time frame:
At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
Reported as:
Geometric mean · h*pg/mL
PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001
h*pg/mLCHF6001
PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF600172403 ± 28.4
PrimaryPK Parameter -- t(1/2_inh) -- Plasma -- CHF6001

t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001

Time frame:
Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
Reported as:
Median · h
PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001
hCHF6001
PK Parameter -- t(1/2_inh) -- Plasma -- CHF600141.5691 (25.930 to 45.159)
PrimaryPK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001

Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).

Time frame:
At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
Reported as:
Geometric mean · Ratio
PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001
RatioCHF6001
PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF60010.4977 ± 26.8
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total

Urine excreted fraction for cumulative \[14\^C\] total.

Time frame:
Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
Reported as:
Mean · Cumulative % of dose excreted in urine
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total
Cumulative % of dose excreted in urineCHF6001
0-4 h1.99 ± 0.523
4-8 h3.26 ± 0.552
8-12 h3.93 ± 0.549
12-24 h5.24 ± 0.554
24-48 h6.77 ± 0.519
48-72 h7.35 ± 0.553
72-96 h7.64 ± 0.622
96-120 h7.80 ± 0.673
120-144 h7.89 ± 0.703
144-168 h7.96 ± 0.720
168-192 h8.01 ± 0.729
192-216 h8.06 ± 0.763
216-240 h8.10 ± 0.771
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001

Urine excreted fraction for cumulative \[14\^C\]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.

Time frame:
Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
Reported as:
Mean · (%) percent of injected [14C]-CHF6001
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001
(%) percent of injected [14C]-CHF6001CHF6001
0-4 h0.00 ± 0.00
0-8 h0.00 ± 0.00
0-12 h0.00 ± 0.00
0-24 h0.00 ± 0.00
0-48 h0.00 ± 0.00
0-72 h0.00 ± 0.00
0-96 h0.00 ± 0.00
0-120 h0.00 ± 0.00
0-144 h0.00 ± 0.00
0-168 h0.00 ± 0.00
0-192 h0.00 ± 0.00
0-216 h0.00 ± 0.00
0-240 h0.00 ± 0.00
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total

Fecal excreted fraction for cumulative \[14\^C\] total.

Time frame:
Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
Reported as:
Mean · Cumulative % of dose excreted in feces
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total
Cumulative % of dose excreted in fecesCHF6001
0-24 h7.64 ± 12.0
24-48 h38.9 ± 20.6
48-72 h57.7 ± 8.53
72-96 h64.9 ± 4.26
96-120 h68.6 ± 2.35
120-144 h69.6 ± 2.08
144-168 h70.0 ± 2.09
168-192 h70.5 ± 2.19
192-216 h70.7 ± 2.22
216-240 h70.8 ± 2.26
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001

Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

Time frame:
Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
Reported as:
Mean · (%) percent of injected [14C]-CHF6001
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001
(%) percent of injected [14C]-CHF6001CHF6001
0-24 h0.0435 ± 0.0676
0-48 h0.1748 ± 0.0895
0-72 h0.2507 ± 0.0855
0-96 h0.2816 ± 0.0685
0-120 h0.3048 ± 0.0660
0-144 h0.3060 ± 0.0642
0-168 h0.3060 ± 0.0642
0-192 h0.3060 ± 0.0642
0-216 h0.3060 ± 0.0642
0-240 h0.3060 ± 0.0642
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total

Urine and fecal excreted fraction for cumulative \[14\^C\] total.

Time frame:
Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
Reported as:
Mean · Cumulative % of dose excreted
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total
Cumulative % of dose excretedCHF6001
0-4 h1.99 ± 0.523
4-8 h3.26 ± 0.552
8-12 h3.93 ± 0.549
12-24 h12.9 ± 12.3
24-48 h45.6 ± 20.8
48-72 h65.1 ± 8.67
72-96 h72.5 ± 4.12
96-120 h76.4 ± 2.46
120-144 h77.5 ± 2.23
144-168 h77.9 ± 2.32
168-192 h78.5 ± 2.46
192-216 h78.7 ± 2.51
216-240 h78.9 ± 2.58
PrimaryPK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001

Urine and Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

Time frame:
Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
Reported as:
Mean · (%) percent of injected [14C]-CHF6001
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001
(%) percent of injected [14C]-CHF6001CHF6001
0-24 h0.0435 ± 0.0676
0-48 h0.1748 ± 0.0895
0-72 h0.2507 ± 0.0855
0-96 h0.2816 ± 0.0685
0-120 h0.3048 ± 0.0660
0-144 h0.3060 ± 0.0642
0-168 h0.3060 ± 0.0642
0-192 h0.3060 ± 0.0642
0-216 h0.3060 ± 0.0642
0-240 h0.3060 ± 0.0642

Adverse events

Collected over Adverse events were monitored from the time of the Informed Consent signature (screening visit at 31 to 3 days before the study treatment administration) until the subject's study participation ended (follow-up phone call or visit at 7 to 10 days after discharge or premature discontinuation).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHF60010/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventCHF6001
CoughRespiratory, thoracic and mediastinal disorders1/8
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/8
Abdominal pain lowerGastrointestinal disorders1/8

Baseline characteristics

Healthy male subjects.

Age, Continuous
Age, Continuous(years)CHF6001
Mean36.3 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)CHF6001
Female0
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHF6001
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)CHF6001
United Kingdom8
Body mass index
Body mass index(kg/m^2)CHF6001
Mean28.09 ± 4.73
08

Study locations

1 site
  • Covance - Clinical Research Unit
    Leeds, LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2021, 1 month.

Results were first posted in Mar 2024, 2 years 10 months after primary completion.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 1 month is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 16, 2021
StartActual
Mar 10, 2021
Primary completionActual
Apr 29, 2021
CompletionActual
Apr 29, 2021
Results first posted
Mar 18, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04756960
Responsible party
Sponsor
First posted
Feb 16, 2021
Start date
Mar 10, 2021
Primary completion
Apr 29, 2021
Completion
Apr 29, 2021
Results posted
Mar 18, 2024
Last update
Mar 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion